Jasper Therapeutics (NASDAQ:JSPR) Trading 8% Higher – Still a Buy?

Jasper Therapeutics, Inc. (NASDAQ:JSPR)’s stock price traded up 8% on Wednesday . The stock traded as high as $0.47 and last traded at $0.4545. 341,917 shares were traded during mid-day trading, a decline of 41% from the average daily volume of 579,155 shares. The stock had previously closed at $0.4210.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on JSPR shares. UBS Group started coverage on Jasper Therapeutics in a report on Monday, March 23rd. They set a “neutral” rating on the stock. TD Cowen cut Jasper Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Tuesday, April 21st. Finally, Royal Bank Of Canada set a $3.00 price target on Jasper Therapeutics and gave the stock a “sector perform” rating in a research report on Friday, May 15th. Five analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $13.14.

Jasper Therapeutics Stock Up 8.0%

The firm has a market capitalization of $12.73 million, a price-to-earnings ratio of -0.14 and a beta of 3.08. The firm’s 50 day moving average is $0.70 and its 200 day moving average is $1.14.

Jasper Therapeutics (NASDAQ:JSPR) last announced its earnings results on Thursday, May 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.08. On average, sell-side analysts predict that Jasper Therapeutics, Inc. will post -1.67 earnings per share for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

A number of institutional investors have recently modified their holdings of JSPR. Velan Capital Investment Management LP boosted its holdings in Jasper Therapeutics by 86.1% in the third quarter. Velan Capital Investment Management LP now owns 2,668,395 shares of the company’s stock worth $6,206,000 after purchasing an additional 1,234,567 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Jasper Therapeutics by 6,394.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,746,492 shares of the company’s stock valued at $3,196,000 after buying an additional 1,719,602 shares in the last quarter. Acorn Capital Advisors LLC bought a new position in Jasper Therapeutics during the third quarter valued at about $3,291,000. Kingdon Capital Management L.L.C. lifted its position in shares of Jasper Therapeutics by 93.5% in the third quarter. Kingdon Capital Management L.L.C. now owns 1,324,845 shares of the company’s stock worth $3,153,000 after buying an additional 640,138 shares during the last quarter. Finally, Millennium Management LLC lifted its position in shares of Jasper Therapeutics by 194.2% in the fourth quarter. Millennium Management LLC now owns 1,073,783 shares of the company’s stock worth $1,965,000 after buying an additional 708,844 shares during the last quarter. Institutional investors and hedge funds own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.